A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

Inclusion Criteria: * Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for Guillain Barré Syndrome * Onset of GBS-related weakness ≤14 days prior to infusion * GBS-DS score of 3, 4, or 5 Exclusion Criteria: * Clinically significant findings that may interfere with the conduct of the study or the interpretation of the data * Be at risk of suicide or self-harm * Received previous treatment with plasma exchange for GBS * Any diagnosis of a variant of GBS * Have a history of anaphylaxis or severe systemic response to immunoglobulin * Documented, clinically significant, pre-existing polyneuropathy from another cause * Clinically significant intercurrent illness, medical condition, or medical history * History of chronic use of steroid or immunosuppressant medication * Active alcohol, drug, or substance abuse * Females who are pregnant, breast feeding, or unable or unwilling to use highly effective methods of contraception throughout the study